HER2-Negative Breast Cancer Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AstraZeneca, Laekna, Novartis, Roche, Eli Lilly

HER2-Negative Breast Cancer Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AstraZeneca, Laekna, Novartis, Roche, Eli Lilly
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 85+ key pharma and biotech companies are working on 85+ pipeline drugs in the HER2-Negative Breast Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

HER2-Negative Breast Cancer Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the HER2-Negative Breast Cancer Market. 

The HER2-Negative Breast Cancer Pipeline report embraces in-depth commercial, regulatory, and HER2-Negative Breast Cancer clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging HER2-Negative Breast Cancer drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

HER2-Negative Breast Cancer Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for HER2-Negative Breast Cancer treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different HER2-Negative Breast Cancer therapies segmented into early-stage, mid-stage, and late-stage clinical development.

  • It outlines the major HER2-Negative Breast Cancer companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the HER2-Negative Breast Cancer drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the HER2-Negative Breast Cancer therapeutic market.

Analysis of Emerging HER2-Negative Breast Cancer Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued and inactive candidates

Route of Administration

HER2-Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Parenteral

  • Intravitreal

  • Subretinal

  • Topical

Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Learn How the HER2-Negative Breast Cancer Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @


HER2-Negative Breast Cancer Therapeutics Landscape

There are approx. 85+ key companies developing therapies for HER2-Negative Breast Cancer. Currently, Jiangsu HengRui Medicine is leading the therapeutics market with its HER2-Negative Breast Cancer drug candidates in the most advanced stage of clinical development.

HER2-Negative Breast Cancer Companies Actively Working in the Therapeutic Market Include:

  • AstraZeneca

  • Laekna

  • Novartis

  • Jiangsu HengRui Medicine

  • Roche

  • Olema Pharmaceuticals

  • Haihe Biopharma

  • G1 Therapeutics

  • Merck

  • Chia Tai Tianqing Pharmaceutical

  • Tyme

  • Radius Pharmaceuticals

  • H3 Biomedicine

  • Eli Lilly and Company

  • Eagle Pharmaceuticals

And Many Others

Emerging and Marketed HER2-Negative Breast Cancer Drugs Covered in the Report Include:

  • Capivasertib + Fulvestrant: AstraZeneca

Capivasertib (AZD5363) is a potent selective oral inhibitor of all three isoforms of the serine/threonine kinase AKT. Capivasertib in combination with fulvestrant is currently in phase III clinical studies for the treatment of patients with locally advanced (inoperable) or metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) breast cancer following recurrence or progression on or after aromatase inhibitor (AI) therapy.

  • Dalpiciclib: Jiangsu HengRui Medicine

Dalpiciclib (formerly SHR 6390) is an orally administered small molecule and selective cyclin-dependent kinase (CDK)-4/6 inhibitor. Dalpiciclib in Combination with Letrozole or Anastrozole or Fulvestrant is in Phase III clinical evaluation in patients with HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer.

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and HER2-Negative Breast Cancer Companies Working in the Market @ https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. HER2-Negative Breast Cancer Treatment Patterns

4. HER2-Negative Breast Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. HER2-Negative Breast Cancer Late Stage Products (Phase-III)

7. HER2-Negative Breast Cancer Mid-Stage Products (Phase-II)

8. HER2-Negative Breast Cancer Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. HER2-Negative Breast Cancer Discontinued Products

13. HER2-Negative Breast Cancer Product Profiles

14. Major HER2-Negative Breast Cancer Companies in the Market

15. Key Products in the HER2-Negative Breast Cancer Therapeutics Segment

16. Dormant and Discontinued Products

17. HER2-Negative Breast Cancer Unmet Needs

18. HER2-Negative Breast Cancer Future Perspectives

19. HER2-Negative Breast Cancer Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @ 




About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Dense Deposit Disease Market

“Dense Deposit Disease Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Dense Deposit Disease market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Dense Deposit Disease market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research